Sökresultat

We ended the MultiPark year in December as we started it in January: with a MultiPark Retreat! The December retreat was our first big meeting IRL after the pandemic, and it turned out to be a much appreciated event. Thank you to all participants, and thank you once again to the retreat organizing committee for doing such a great job! 2022 was a year of “reopening”. Like a butterfly spreads its win

https://www.multipark.lu.se/article/multipark-closing-circle-2022-and-looking-forward-2023 - 2025-12-15

Katrine Skovgård’s Ph.D. project sheds light on the dysfunctions in the brain through which dopaminergic pharmacotherapies for Parkinson’s disease affect motor behaviors. January 19, she defends her thesis. She explains how better experimental models might improve future translational research on dyskinesia. You presented your research at the MultiPark Café recently. But for those who could not at

https://www.multipark.lu.se/article/why-dopamine-receptor-type-matters-phd-interview-katrine-skovgard - 2025-12-15

At the end of October 2022, the Swedish Medical Products Agency gave the go-ahead for a clinical trial of the stem cell-based therapy STEM-PD for the treatment of Parkinson’s disease. The cells, generated from embryonic stem cells, have been in development for several years and will now be transplanted into patients with Parkinson’s to replace nerve cells lost due to the disease. The clinical tria

https://www.multipark.lu.se/article/nerve-cells-could-transform-treatment-parkinsons - 2025-12-15

Huntington's disease is known as the "dance disease" due to the patient's characteristic motor symptoms. However, Elna Dickson's Ph.D. project shows that the disease also leads to pathological changes outside the brain. February 17, she defends her thesis about metabolic alterations in Huntington's disease. Now, she shares perspectives on her research journey. Tell us about your research! "Hunting

https://www.multipark.lu.se/article/huntingtons-metabolic-dysfunctions-phd-interview-elna-dickson - 2025-12-15

The aggregation of the protein Amyloid-beta (Abeta) into plaques outside the nerve cells has been recognized in patients with Alzheimer’s disease since 1905. But eliminating the plaques has not helped patients so far. Still, Tomas Roos thinks that Abeta matters, but we may need to focus on the aggregates elsewhere. On February 17, he defends his thesis about prion-like proteins in neurodegeneratio

https://www.multipark.lu.se/article/does-alzheimers-disease-start-inside-neurons-phd-interview-tomas-roos - 2025-12-15

On 13th of February, a transplant of stem cell-derived nerve cells was administered to a person with Parkinson’s at Skåne University Hospital, Sweden. The product has been developed by Lund University and it is now being tested in patients for the first time. The transplantation product is generated from embryonic stem cells and functions to replace the dopamine nerve cells which are lost in the p

https://www.multipark.lu.se/article/first-patient-receives-milestone-stem-cell-based-transplant-parkinsons-disease - 2025-12-15

The boundaries between biology and technology are becoming blurred. Researchers at Linköping, Lund, and Gothenburg universities in Sweden have successfully grown electrodes in living tissue using the body’s molecules as triggers. The result, published in the journal Science, paves the way for the formation of fully integrated electronic circuits in living organisms. This news was initially publish

https://www.multipark.lu.se/article/electrodes-grown-brain - 2025-12-15

Kajsa Brolin explores how our genes and environment affect the risk of developing Parkinson’s disease. March 27, she defends her Ph.D. project partly based on MultiPark’s biobank sample collection. Here, she tells about the newly discovered genetic risk factor that might be specific to people in the southern part of Sweden. And is coffee really protective? Tell us about your research! “My research

https://www.multipark.lu.se/article/genes-and-environment-pd-phd-interview-kajsa-brolin - 2025-12-15

After a decade of protocol development and preparations, MultiPark researchers have finally launched the clinical trial. Recently, dopamine-producing cells generated from embryonic stem cells were transplanted into the first Parkinson's patient at Skåne University Hospital. During the autumn 2022, the Swedish MPA (Läkemedelsverket) approved the clinical STEM-PD study. Several of MultiParks PIs hav

https://www.multipark.lu.se/article/stem-pd-bench-bedside-story-multipark-researchers-0 - 2025-12-15

Looking for the next step in your career? In need of some scientific inspiration? Or are you just curious about what MultiPark´s senior researchers are doing and their professional journey? Listen to MultiPark’s new podcast series “Meet our scientists”! In a newly launched podcast, young MultiPark researchers interview our research group leaders about their academic journey and main scientific foc

https://www.multipark.lu.se/article/meet-our-scientists-new-podcast-young-multipark-researchers - 2025-12-15

In the early 1950s, no one knew what caused Parkinson's disease. Then, Arvid Carlsson's discovery of dopamine opened the door to world-leading transplantations for Parkinson's patients. Thanks to the pioneering basic research at MultiPark, stemcell-derived neural cells can now be tested in a clinical trial for the first time. In Parkinson's disease, the nerve cells in an area of the brain that con

https://www.multipark.lu.se/article/world-parkinsons-day-transplantations-parkinsons-disease-time-travel - 2025-12-15

Genetics are one of the keys to understanding neurodegenerative disease. That is why MultiPark researchers with expertise in genetics gather across research groups. Genetics of neurodegenerative diseases is a new special interest group (SIG) addressing scientific and technological needs to unravel the genetics behind diseases such as Parkinson’s and Alzheimer’s. Andreas Puschmann tells about how h

https://www.multipark.lu.se/article/genetics-neurodegenerative-diseases-special-interest-group - 2025-12-15

Three researchers at Lund University, all with a long list of significant research credentials, have been awarded the ERC Advanced Grant worth EUR 2.5 million each to further develop and advance their research projects. Two of them are MultiPark research leaders. They do research on chaperone proteins’ function in neurodegenerative diseases and blood tests for rapid screening of drugs in the treat

https://www.multipark.lu.se/article/double-success-multipark-research-groups-prestigious-eu-grant-round - 2025-12-15

Several Nobel laureates, renowned scientists, and successful biotech entrepreneurs are coming to Lund in May to participate in the Lund Spring Symposium, an international pharmaceutical symposium sponsored by MultiPark. Sarah Tabrizi, a high profile Huntington researcher, and some of MultiPark's own researchers will speak. Medications are the physician's primary tool when treating their patients,

https://www.multipark.lu.se/article/superstars-coming-lund-pharmaceutical-symposium-sponsored-multipark - 2025-12-15

Recent studies indicate that acquired brain injuries, such as traumatic brain injury, trigger potentially harmful responses that may lead to neurodegenerative pathology. “Acquired brain injuries and their links to neurodegeneration diseases” is a new special interest group (SIG) collaborating across research groups to elucidate molecular processes that may mediate the relation between acquired bra

https://www.multipark.lu.se/article/acquired-brain-injuries-special-interest-group - 2025-12-15

Researchers at Lund University in Sweden believe they have identified a gene variant that can cause cerebral small vessel disease and stroke. The study is published in Neurology Genetics. Read more about this discovery.  Article in Neurology Genetics MAP3K6 Mutations in a Neurovascular Disease Causing Stroke, Cognitive Impairment, and Tremor (Neurology Genetics, February 2021)

https://www.multipark.lu.se/article/new-gene-variant-linked-stroke - 2025-12-15

Overexpression of the Parkinson-related protein, α-synuclein, leads to blood-brain barrier leakage and pericyte activation in mice. A study published in Scientific Reports identifies pericytes as potential target cells for early interventions. Parkinson’s disease is a movement disorder caused by the accumulation and aggregation of α-synuclein and degeneration of dopaminergic neurons. Disruption of

https://www.multipark.lu.se/article/pericytes-link-between-parkinson-related-protein-and-blood-brain-barrier-disruption - 2025-12-15

Researchers from Lund Stem Cell Center highlight the importance of controlling viral elements that reside in the genome and how their activation during development may contribute to brain disorders later in life. Around 10% of the human genome is composed of DNA sequences originating from viruses that infected our ancestors throughout the millions of years of our evolution. Under normal conditions

https://www.multipark.lu.se/article/activation-ancient-viruses-during-brain-development-causes-inflammation - 2025-12-15

During her PhD studies Shelby Shrigley has been exploring patient-specific cell replacement therapy for Parkinson's disease. Defending her PhD thesis on March 12th, here Shelby tells us about her research within the Developmental and Regenerative Neurobiology research group led by Prof. Malin Parmar and her time spent at Lund Stem Cell Center. Can you tell us about your PhD research? The main focu

https://www.multipark.lu.se/article/phd-defence-interview-shelby-shrigley - 2025-12-15

Alzheimer’s disease seems to progress faster in women than in men. The protein tau accumulates at a higher rate in women, according to research from Lund University in Sweden. The study was recently published in Brain. Over 30 million people suffer from Alzheimer’s disease worldwide, making it the most common form of dementia. Tau and beta-amyloid are two proteins known to aggregate and accumulate

https://www.multipark.lu.se/article/women-accumulate-alzheimers-related-protein-faster - 2025-12-15